Salix Pharmaceuticals

salix.com

Salix Pharmaceuticals is a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders. For more than 20 years, we have licensed, developed, and marketed innovative products to treat GI problems. It’s our mission to give healthcare providers and patients the most effective solutions in gastroenterology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

news image

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More

Business Insights, PHARMACY MARKET

ENANTA PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR EDP-323, ITS ORAL, L-PROTEIN INHIBITOR IN DEVELOPMENT

Businesswire | April 10, 2023

news image

Enanta Pharmaceuticals, Inc. a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). "Receiving Fast Track designation from the FDA underscores EDP-323’s potential as a once-daily, oral therapeutic for the treat...

Read More

Pharmacy Market

MEDICAL LEVERAGE, A COMMUNICATIONS COMPANY POSITIONS ITSELF FOR 2022 GROWTH

medical leverage | January 15, 2022

news image

medical leverage, a communications company is pleased to announce the promotion of Justin Reed to VP of Finance, Alexandra Rivers to HR and Training Manager, and Janeanne Josephson to Associate Marketing Manager. These changes drive the company's mission to meet the challenges of today's unique market. With the additional hiring of several project managers to the team, ml is positioning itself well for growth in 2022. These promotions are all important shifts in responsibi...

Read More

Pharmacy Market

CASCADE CHEMISTRY INITIATES $14 MILLION EXPANSION OF CGMP PHARMACEUTICAL MANUFACTURING CAPACITY

Cascade Chemistry | February 19, 2021

news image

Cascade Chemistry, a main pharmaceutical contract development and manufacturing organization, today declared inception of development of new offices intended to expand the organization's ability to manufacture APIs (dynamic pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures). The new offices, expected to be operational in the main quarter of 2022, will eventually expand the organization's floor space just about three-overl...

Read More
news image

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More
news image

Business Insights, PHARMACY MARKET

ENANTA PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR EDP-323, ITS ORAL, L-PROTEIN INHIBITOR IN DEVELOPMENT

Businesswire | April 10, 2023

Enanta Pharmaceuticals, Inc. a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). "Receiving Fast Track designation from the FDA underscores EDP-323’s potential as a once-daily, oral therapeutic for the treat...

Read More
news image

Pharmacy Market

MEDICAL LEVERAGE, A COMMUNICATIONS COMPANY POSITIONS ITSELF FOR 2022 GROWTH

medical leverage | January 15, 2022

medical leverage, a communications company is pleased to announce the promotion of Justin Reed to VP of Finance, Alexandra Rivers to HR and Training Manager, and Janeanne Josephson to Associate Marketing Manager. These changes drive the company's mission to meet the challenges of today's unique market. With the additional hiring of several project managers to the team, ml is positioning itself well for growth in 2022. These promotions are all important shifts in responsibi...

Read More
news image

Pharmacy Market

CASCADE CHEMISTRY INITIATES $14 MILLION EXPANSION OF CGMP PHARMACEUTICAL MANUFACTURING CAPACITY

Cascade Chemistry | February 19, 2021

Cascade Chemistry, a main pharmaceutical contract development and manufacturing organization, today declared inception of development of new offices intended to expand the organization's ability to manufacture APIs (dynamic pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures). The new offices, expected to be operational in the main quarter of 2022, will eventually expand the organization's floor space just about three-overl...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us